Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
Daiichi Sankyo has set an ambitious goal to secure a position among the top five global oncology companies by 2035, as outlined in its newly unveiled five-year business plan. The Japanese pharmaceutical giant is leveraging its expertise in antibody-drug conjugates to drive this transformation, which is expected to significantly enhance its market presence in the…









